BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:adalimumab-atto (Amjevita) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of adalimumab-atto (Amjevita)\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07486843-9686@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:adalimumab-atto (Amjevita): Phase 4 readout est. (NCT07486843)
DESCRIPTION:adalimumab-atto (Amjevita)\, phase 4\, Psoriatic Arthritis.\nSt
 udy: Preventing Structural Damage in Early Psoriatic Arthritis\nEstimated 
 primary completion: 31 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/adalimumab-atto-amjevita#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07486843
URL:https://assetmemo.bio/drug/adalimumab-atto-amjevita#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
